171 related articles for article (PubMed ID: 34414983)
41. Cardiac sympathetic "morbidity" might reflect the neurobiology of early Parkinson's disease.
Yoo SW; Oh YS; Ryu DW; Ha S; Lyoo CH; Kim Y; Yoo JY; Kim JS
J Neurol; 2024 Feb; 271(2):944-954. PubMed ID: 37864716
[TBL] [Abstract][Full Text] [Related]
42. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects.
Booij J; de Jong J; de Bruin K; Knol R; de Win MM; van Eck-Smit BL
J Nucl Med; 2007 Mar; 48(3):359-66. PubMed ID: 17332612
[TBL] [Abstract][Full Text] [Related]
43. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison.
Walker Z; Costa DC; Walker RW; Lee L; Livingston G; Jaros E; Perry R; McKeith I; Katona CL
Neurology; 2004 May; 62(9):1568-72. PubMed ID: 15136683
[TBL] [Abstract][Full Text] [Related]
44. Precise Evaluation of Striatal Oxidative Stress Corrected for Severity of Dopaminergic Neuronal Degeneration in Patients with Parkinson's Disease: A Study with 62Cu-ATSM PET and 123I-FP-CIT SPECT.
Neishi H; Ikawa M; Okazawa H; Tsujikawa T; Arishima H; Kikuta KI; Yoneda M
Eur Neurol; 2017; 78(3-4):161-168. PubMed ID: 28848099
[TBL] [Abstract][Full Text] [Related]
45. [Cardiac sympathetic dysfunction in Parkinson's disease--relationship between results of 123I-MIBG scintigraphy and autonomic nervous function evaluated by the Valsalva maneuver].
Oka H; Yoshioka M; Morita M; Mochio S; Inoue K
Rinsho Shinkeigaku; 2003 Aug; 43(8):465-9. PubMed ID: 14658397
[TBL] [Abstract][Full Text] [Related]
46. Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer's disease.
Shimizu S; Hirao K; Kanetaka H; Namioka N; Hatanaka H; Hirose D; Fukasawa R; Umahara T; Sakurai H; Hanyu H
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):184-192. PubMed ID: 26233438
[TBL] [Abstract][Full Text] [Related]
47.
Yoshii F; Moriya Y; Ohnuki T; Ryo M; Takahashi W; Kohara S; Hashimoto J
Clin Neurol Neurosurg; 2017 Sep; 160():73-77. PubMed ID: 28689103
[TBL] [Abstract][Full Text] [Related]
48. 123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms.
Filippi L; Manni C; Pierantozzi M; Brusa L; Danieli R; Stanzione P; Schillaci O
Nucl Med Commun; 2005 May; 26(5):421-6. PubMed ID: 15838424
[TBL] [Abstract][Full Text] [Related]
49. Differences in nigro-striatal impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study.
Rossi C; Frosini D; Volterrani D; De Feo P; Unti E; Nicoletti V; Kiferle L; Bonuccelli U; Ceravolo R
Eur J Neurol; 2010 Apr; 17(4):626-30. PubMed ID: 20050904
[TBL] [Abstract][Full Text] [Related]
50. Validation of a standardized normalization template for statistical parametric mapping analysis of 123I-FP-CIT images.
Kas A; Payoux P; Habert MO; Malek Z; Cointepas Y; El Fakhri G; Chaumet-Riffaud P; Itti E; Remy P
J Nucl Med; 2007 Sep; 48(9):1459-67. PubMed ID: 17704252
[TBL] [Abstract][Full Text] [Related]
51. A diagnostic strategy for Lewy body disease using DAT-SPECT, MIBG and Combined index.
Sakamoto F; Shiraishi S; Ogasawara K; Tsuda N; Nakagawa M; Tomiguchi S; Yamashita Y
Ann Nucl Med; 2020 Jun; 34(6):415-423. PubMed ID: 32301068
[TBL] [Abstract][Full Text] [Related]
52. Iodine-123 labelled N-(2-fluoroethyl)-2 beta-carbomethoxy-3 beta-(4-iodophenyl)nortropane for dopamine transporter imaging in the living human brain.
Kuikka JT; Akerman K; Bergström KA; Karhu J; Hiltunen J; Haukka J; Heikkinen J; Tiihonen J; Wang S; Neumeyer JL
Eur J Nucl Med; 1995 Jul; 22(7):682-6. PubMed ID: 7498231
[TBL] [Abstract][Full Text] [Related]
53. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction.
Sakakibara R; Shinotoh H; Uchiyama T; Yoshiyama M; Hattori T; Yamanishi T
J Neurol Sci; 2001 Jun; 187(1-2):55-9. PubMed ID: 11440745
[TBL] [Abstract][Full Text] [Related]
54. Differences in striatal dopamine transporter density between tremor dominant and non-tremor Parkinson's disease.
Kaasinen V; Kinos M; Joutsa J; Seppänen M; Noponen T
Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1931-7. PubMed ID: 24867256
[TBL] [Abstract][Full Text] [Related]
55. 123I-ioflupane brain SPECT and 123I-MIBG cardiac planar scintigraphy combined use in uncertain parkinsonian disorders.
Nuvoli S; Spanu A; Piras MR; Nieddu A; Mulas A; Rocchitta G; Galleri G; Serra PA; Madeddu G
Medicine (Baltimore); 2017 May; 96(21):e6967. PubMed ID: 28538394
[TBL] [Abstract][Full Text] [Related]
56. Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake.
Benamer HT; Patterson J; Wyper DJ; Hadley DM; Macphee GJ; Grosset DG
Mov Disord; 2000 Jul; 15(4):692-8. PubMed ID: 10928580
[TBL] [Abstract][Full Text] [Related]
57. Clinical correlation of the binding potential with 123I-FP-CIT in de novo idiopathic Parkinson's disease patients.
Berti V; Pupi A; Ramat S; Vanzi E; De Cristofaro MT; Pellicanò G; Mungai F; Marini P; Sorbi S
Eur J Nucl Med Mol Imaging; 2008 Dec; 35(12):2220-6. PubMed ID: 18649079
[TBL] [Abstract][Full Text] [Related]
58. Dopaminergic Correlates of Orthostatic Hypotension in de novo Parkinson's Disease.
Umehara T; Oka H; Nakahara A; Shiraishi T; Sato T; Matsuno H; Komatsu T; Omoto S; Murakami H; Iguchi Y
J Parkinsons Dis; 2021; 11(2):665-673. PubMed ID: 33361609
[TBL] [Abstract][Full Text] [Related]
59. Clinical features and 123I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson's disease.
Benítez-Rivero S; Marín-Oyaga VA; García-Solís D; Huertas-Fernández I; García-Gómez FJ; Jesús S; Cáceres MT; Carrillo F; Ortiz AM; Carballo M; Mir P
J Neurol Neurosurg Psychiatry; 2013 Feb; 84(2):122-9. PubMed ID: 22906618
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
